Daily Archive: November 8, 2011

Nov 08

Heart failure patients should be encouraged to exercise

Previously exercise training was thought to be harmful in congestive heart failure and it was thought that bed rest might minimize symptom whereas physical activity might accelerate the progression of LV dysfunction. But many studies have shown today that exercise programmes induce improved exercise capacity. Though the quality of life improvement has not been reported …

Continue reading »

Nov 08

Patient perspectives and symptom differences in acute coronary syndrome

(Dr Varghese, Sreelaxmi M A, Santosh M J, Shetty GG, Kiron V, Patil CB and Iyengar SS) As per a study to be presented in 63rd CSI at Mumbai in December by Dr Varghese G and group from department of cardiology, St. Johns Medical College, Bangalore; diabetes, hypertension, dyslipidemia and increased age are linked to NSTEMI …

Continue reading »

Nov 08

Coronary calcification linked colorectal cancer

Patients with coronary calcification had a 40% prevalence of colorectal adenomas compared with 30% in patients with no coronary calcification (P<0.01) according to a presentation at the American Association for Cancer Research Frontiers in Cancer Prevention Research conference by Moon Hee Yang, of Samsung Medical Center in Seoul, Korea.

Nov 08

Facts and figures in cardiology

NSAIDS interfere with BP-lowering of all antihypertensive drug classes except calcium antagonists. (Hypertension 2000;36:461-465)

Nov 08

Do you know?

There has been 83% reduction in the size of ICD since its introduction in 1980s. At the time of its introduction, ICD can size measured about 209cc. The present generation ICDs measure about 36cc making it more convenient for the patients. (Dr Niti Chadha and Dr Aparna Jaswal from Fortis Escorts Heart Institute in Cardiology …

Continue reading »

Nov 08

Ten points about Telmisartan a 3rd generation ARB

Dr Pritam Patil and Dr Suman Bhandari 1.   Blockade of the RAS is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua. 2.  Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, …

Continue reading »

Nov 08

Late breaking Trials in TCT

At this year’s Transcatheter Cardiovascular Therapeutics meeting, there are some 20 late-breaking trial presentations, with more than a few that have the potential to impact clinical practice if the results are positive. Three of the late-breaking trials link to PARTNER: Evaluation of the Sapien transcatheter aortic valve (approved by the FDA on Nov. 2). We …

Continue reading »